Amairelys Belen Barroeta Seijas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Amairelys Belen Barroeta Seijas has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
Angela Santoni
Neuromed IRCCS Pozzilli, Isernia Italy
3 shared publications- Francesca Di Rosa
Institute of Molecular Biology and Pathology, National Research Council of Italy (CNR), Rome, Italy
3 shared publications Sonia Simonetti
Institute of Molecular Biology and Pathology National Research Council (CNR) Rome Italy
3 shared publicationsAlessandra Soriani
Department of Molecular Medicine, University of Rome "Sapienza", Rome, Italy
2 shared publicationsAntonella Naldini
Department of Molecular and Developmental Medicine University of Siena Siena Italy
2 shared publicationsDaniele Runci
Istituto Pasteur Italia - Fondazione Cenci Bolognetti, Rome, Italy
2 shared publications
Latest Publications
- Open Access
- 7 September 2022
- Published by Wiley in Cell Biochemistry and Function
- Vol. 40 (7) , 718-728
Mouse dendritic cells in the steady state: Hypoxia, autophagy, and stem cell factor
Dendritic cells (DCs) are innate immune cells with a central role in immunity and tolerance. Under steady‐state, DCs are scattered in tissues as resting cells. Upon infection or injury, DCs get activated and acquire the full capacity to prime antigen‐specific CD4+ and CD8+ T cells, thus bridging innate and adaptive immunity. By secreting different sets of cytokines and chemokines, DCs orchestrate diverse types of immune responses, from a classical proinflammatory to an alternative pro‐repair one. DCs are highly heterogeneous, and physiological differences in tissue microenvironments greatly contribute to variations in DC phenotype. Oxygen tension is normally low in some lymphoid areas, including bone marrow (BM) hematopoietic niches; nevertheless, the possible impact of tissue hypoxia on DC physiology has been poorly investigated. We assessed whether DCs are hypoxic in BM and spleen, by staining for hypoxia‐inducible‐factor‐1α subunit (HIF‐1α), the master regulator of hypoxia‐induced response, and pimonidazole (PIM), a hypoxic marker, and by flow cytometric analysis. Indeed, we observed that mouse DCs have a hypoxic phenotype in spleen and BM, and showed some remarkable differences between DC subsets. Notably, DCs expressing membrane c‐kit, the receptor for stem cell factor (SCF), had a higher PIM median fluorescence intensity (MFI) than c‐kit− DCs, both in the spleen and in the BM. To determine whether SCF (a.k.a. kit ligand) has a role in DC hypoxia, we evaluated molecular pathways activated by SCF in c‐kit+ BM‐derived DCs cultured in hypoxic conditions. Gene expression microarrays and gene set enrichment analysis supported the hypothesis that SCF had an impact on hypoxia response and inhibited autophagy‐related gene sets. Our results suggest that hypoxic response and autophagy, and their modulation by SCF, can play a role in DC homeostasis at the steady state, in agreement with our previous findings on SCF's role in DC survival.
- 7 September 2022
- Published by Wiley in Cell Biochemistry and Function
- Vol. 40 (7) , 718-728
Open AccessMouse dendritic cells in the steady state: Hypoxia, autophagy, and stem cell factor
Dendritic cells (DCs) are innate immune cells with a central role in immunity and tolerance. Under steady‐state, DCs are scattered in tissues as resting cells. Upon infection or injury, DCs get activated and acquire the full capacity to prime antigen‐specific CD4+ and CD8+ T cells, thus bridging innate and adaptive immunity. By secreting different sets of cytokines and chemokines, DCs orchestrate diverse types of immune responses, from a classical proinflammatory to an alternative pro‐repair one. DCs are highly heterogeneous, and physiological differences in tissue microenvironments greatly contribute to variations in DC phenotype. Oxygen tension is normally low in some lymphoid areas, including bone marrow (BM) hematopoietic niches; nevertheless, the possible impact of tissue hypoxia on DC physiology has been poorly investigated. We assessed whether DCs are hypoxic in BM and spleen, by staining for hypoxia‐inducible‐factor‐1α subunit (HIF‐1α), the master regulator of hypoxia‐induced response, and pimonidazole (PIM), a hypoxic marker, and by flow cytometric analysis. Indeed, we observed that mouse DCs have a hypoxic phenotype in spleen and BM, and showed some remarkable differences between DC subsets. Notably, DCs expressing membrane c‐kit, the receptor for stem cell factor (SCF), had a higher PIM median fluorescence intensity (MFI) than c‐kit− DCs, both in the spleen and in the BM. To determine whether SCF (a.k.a. kit ligand) has a role in DC hypoxia, we evaluated molecular pathways activated by SCF in c‐kit+ BM‐derived DCs cultured in hypoxic conditions. Gene expression microarrays and gene set enrichment analysis supported the hypothesis that SCF had an impact on hypoxia response and inhibited autophagy‐related gene sets. Our results suggest that hypoxic response and autophagy, and their modulation by SCF, can play a role in DC homeostasis at the steady state, in agreement with our previous findings on SCF's role in DC survival.
- Open Access
- 28 January 2021
- Published by American Society of Hematology in Blood
- Vol. 137 (4) , 493-499
Absent B cells, agammaglobulinemia, and hypertrophic cardiomyopathy in folliculin-interacting protein 1 deficiency
Agammaglobulinemia is the most profound primary antibody deficiency that can occur due to an early termination of B-cell development. We here investigated 3 novel patients, including the first known adult, from unrelated families with agammaglobulinemia, recurrent infections, and hypertrophic cardiomyopathy (HCM). Two of them also presented with intermittent or severe chronic neutropenia. We identified homozygous or compound-heterozygous variants in the gene for folliculin interacting protein 1 (FNIP1), leading to loss of the FNIP1 protein. B-cell metabolism, including mitochondrial numbers and activity and phosphatidylinositol 3-kinase/AKT pathway, was impaired. These defects recapitulated the Fnip1−/− animal model. Moreover, we identified either uniparental disomy or copy-number variants (CNVs) in 2 patients, expanding the variant spectrum of this novel inborn error of immunity. The results indicate that FNIP1 deficiency can be caused by complex genetic mechanisms and support the clinical utility of exome sequencing and CNV analysis in patients with broad phenotypes, including agammaglobulinemia and HCM. FNIP1 deficiency is a novel inborn error of immunity characterized by early and severe B-cell development defect, agammaglobulinemia, variable neutropenia, and HCM. Our findings elucidate a functional and relevant role of FNIP1 in B-cell development and metabolism and potentially neutrophil activity.
- 28 January 2021
- Published by American Society of Hematology in Blood
- Vol. 137 (4) , 493-499
Open AccessAbsent B cells, agammaglobulinemia, and hypertrophic cardiomyopathy in folliculin-interacting protein 1 deficiency
Agammaglobulinemia is the most profound primary antibody deficiency that can occur due to an early termination of B-cell development. We here investigated 3 novel patients, including the first known adult, from unrelated families with agammaglobulinemia, recurrent infections, and hypertrophic cardiomyopathy (HCM). Two of them also presented with intermittent or severe chronic neutropenia. We identified homozygous or compound-heterozygous variants in the gene for folliculin interacting protein 1 (FNIP1), leading to loss of the FNIP1 protein. B-cell metabolism, including mitochondrial numbers and activity and phosphatidylinositol 3-kinase/AKT pathway, was impaired. These defects recapitulated the Fnip1−/− animal model. Moreover, we identified either uniparental disomy or copy-number variants (CNVs) in 2 patients, expanding the variant spectrum of this novel inborn error of immunity. The results indicate that FNIP1 deficiency can be caused by complex genetic mechanisms and support the clinical utility of exome sequencing and CNV analysis in patients with broad phenotypes, including agammaglobulinemia and HCM. FNIP1 deficiency is a novel inborn error of immunity characterized by early and severe B-cell development defect, agammaglobulinemia, variable neutropenia, and HCM. Our findings elucidate a functional and relevant role of FNIP1 in B-cell development and metabolism and potentially neutrophil activity.
- Open Access
- 13 February 2019
- Published by Wiley in European Journal of Immunology
- Vol. 49 (4) , 534-545
Dendritic cells modulate c‐kit expression on the edge between activation and death
Dendritic cells (DCs) are key players in immunity and tolerance. Some DCs express c‐kit, the receptor for stem cell factor (SCF), nevertheless c‐kit functional role and the regulation of its expression in DCs are incompletely defined. We recently demonstrated that autocrine SCF sustains a pro‐survival circuit, and that SCF increases phospho‐AKT in c‐kit+ mouse bone marrow‐derived DCs (BMdDCs).Herein we observed that CpG and PolyI:C, two stimuli mimicking bacterial and viral nucleic acids respectively, strongly inhibited c‐kit expression by BMdDCs and spleen DCs in vitro and in vivo. Experiments in IFNARI−/− mice showed that IFN‐I pathway was required for c‐kit down‐regulation in cDC1s, but only partially supported it in cDC2s. Furthermore, CpG and PolyI:C strongly inhibited c‐kit mRNA expression. In agreement with the reduced c‐kit levels, SCF pro‐survival activity was impaired. Thus in the presence of exogenously provided SCF, either PolyI:C or CpG induced spleen DC death in 2 days, while at earlier times IL‐6 and IL‐12 production were slightly increased. In contrast, SCF improved survival of unstimulated spleen DCs expressing high c‐kit levels.Our studies suggest that c‐kit down‐modulation is a previously neglected component of DC response to CpG and PolyI:C, regulating DC survival and ultimately tuning immune response.
- 13 February 2019
- Published by Wiley in European Journal of Immunology
- Vol. 49 (4) , 534-545
Open AccessDendritic cells modulate c‐kit expression on the edge between activation and death
Dendritic cells (DCs) are key players in immunity and tolerance. Some DCs express c‐kit, the receptor for stem cell factor (SCF), nevertheless c‐kit functional role and the regulation of its expression in DCs are incompletely defined. We recently demonstrated that autocrine SCF sustains a pro‐survival circuit, and that SCF increases phospho‐AKT in c‐kit+ mouse bone marrow‐derived DCs (BMdDCs).Herein we observed that CpG and PolyI:C, two stimuli mimicking bacterial and viral nucleic acids respectively, strongly inhibited c‐kit expression by BMdDCs and spleen DCs in vitro and in vivo. Experiments in IFNARI−/− mice showed that IFN‐I pathway was required for c‐kit down‐regulation in cDC1s, but only partially supported it in cDC2s. Furthermore, CpG and PolyI:C strongly inhibited c‐kit mRNA expression. In agreement with the reduced c‐kit levels, SCF pro‐survival activity was impaired. Thus in the presence of exogenously provided SCF, either PolyI:C or CpG induced spleen DC death in 2 days, while at earlier times IL‐6 and IL‐12 production were slightly increased. In contrast, SCF improved survival of unstimulated spleen DCs expressing high c‐kit levels.Our studies suggest that c‐kit down‐modulation is a previously neglected component of DC response to CpG and PolyI:C, regulating DC survival and ultimately tuning immune response.
- Open Access
- 16 February 2017
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 8, 147
GM-CSF Inhibits c-Kit and SCF Expression by Bone Marrow-Derived Dendritic Cells
Stem Cell Factor (SCF), the ligand of c-kit, is a key cytokine for hematopoiesis. Hematopoietic precursors express c-kit, whereas differentiated cells of hematopoietic lineage are negative for this receptor, with the exception of NK cells, mast cells and a few others. While it has long been recognized that dendritic cells (DCs) can express c-kit, several questions remain concerning the SCF/c-kit axis in DCs. This is particularly relevant for DCs found in those organs wherein SCF is highly expressed, including the bone marrow (BM). We characterized c-kit expression by cDCs from BM, and demonstrated a higher proportion of c-kit+ cells among cDC1s than cDC2s in both humans and mice, whereas similar levels of c-kit expression were observed in cDC1s and cDC2s from mouse spleen. To further study c-kit regulation, DCs were generated with GM-CSF from mouse BM, a widely used protocol. CD11c+ cells were purified from pooled non-adherent and slightly adherent cells collected after 7 days of culture, thus obtaining highly purified BM derived DCs (BMdDCs). BMdDCs contained a small fraction of c-kit+ cells, and by re-plating them for 2 days with GM-CSF we obtained a homogeneous population of c-kit+ CD40hi MHCIIhi cells. Not only did BMdDCs express c-kit, but they also produced SCF, and both were striking up-regulated if GM-CSF was omitted after re-plating. Furthermore, a small but significant reduction in BMdDC survival was observed upon SCF silencing. Incubation of BMdDCs with SCF did not modulate antigen presentation ability of these cells, nor it did regulate their membrane expression of the chemokine receptor CXCR4. We conclude that the SCF/c-kit mediated pro-survival circuit may have been overlooked because of the prominent use of GM-CSF in DC cultures in vitro, including those human DC cultures destined for the clinics. We speculate that DCs more prominently rely on SCF in vivo in some microenvironments, with potential implications for Graft Versus Host Disease (GVHD) and anti-tumor immunity.
- 16 February 2017
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 8, 147
Open AccessGM-CSF Inhibits c-Kit and SCF Expression by Bone Marrow-Derived Dendritic Cells
Stem Cell Factor (SCF), the ligand of c-kit, is a key cytokine for hematopoiesis. Hematopoietic precursors express c-kit, whereas differentiated cells of hematopoietic lineage are negative for this receptor, with the exception of NK cells, mast cells and a few others. While it has long been recognized that dendritic cells (DCs) can express c-kit, several questions remain concerning the SCF/c-kit axis in DCs. This is particularly relevant for DCs found in those organs wherein SCF is highly expressed, including the bone marrow (BM). We characterized c-kit expression by cDCs from BM, and demonstrated a higher proportion of c-kit+ cells among cDC1s than cDC2s in both humans and mice, whereas similar levels of c-kit expression were observed in cDC1s and cDC2s from mouse spleen. To further study c-kit regulation, DCs were generated with GM-CSF from mouse BM, a widely used protocol. CD11c+ cells were purified from pooled non-adherent and slightly adherent cells collected after 7 days of culture, thus obtaining highly purified BM derived DCs (BMdDCs). BMdDCs contained a small fraction of c-kit+ cells, and by re-plating them for 2 days with GM-CSF we obtained a homogeneous population of c-kit+ CD40hi MHCIIhi cells. Not only did BMdDCs express c-kit, but they also produced SCF, and both were striking up-regulated if GM-CSF was omitted after re-plating. Furthermore, a small but significant reduction in BMdDC survival was observed upon SCF silencing. Incubation of BMdDCs with SCF did not modulate antigen presentation ability of these cells, nor it did regulate their membrane expression of the chemokine receptor CXCR4. We conclude that the SCF/c-kit mediated pro-survival circuit may have been overlooked because of the prominent use of GM-CSF in DC cultures in vitro, including those human DC cultures destined for the clinics. We speculate that DCs more prominently rely on SCF in vivo in some microenvironments, with potential implications for Graft Versus Host Disease (GVHD) and anti-tumor immunity.
- Open Access
- 1 April 2012
- Published by SAGE Publications in International Journal of Immunopathology and Pharmacology
- Vol. 25 (2) , 407-414
The Impact of TACI Mutations: From Hypogammaglobulinemia in Infancy to Autoimmunity in Adulthood
Common variable immunodeficiency (CVID) is considered the most common symptomatic antibody deficiency and, although mainly reported in adults, it may present from childhood. Few data on the impact of TACI defects on the clinical and immunological status of children are available. We screened 42 hypogammaglobulinemia children to investigate the frequency and mutational features of TACI defects. The genetic, clinical and immunological characterization was extended to 31 relatives of 11 children with TACI mutations. Of interest, our analysis showed a considerably higher mutation frequency in hypogammaglobulinemic children (13/42; 31%) than in other cohorts of adult patients. In seven out of nine families with the C104R variant, the prevalence of autoimmunity was significantly higher in C104R heterozygous relatives (8/15; 53%) than in those with no C104R mutation (1/11; 9%). Our data suggest a different impact of TACI mutations, from hypogammaglobulinemia in children to autoimmune disease in adulthood.
- 1 April 2012
- Published by SAGE Publications in International Journal of Immunopathology and Pharmacology
- Vol. 25 (2) , 407-414
Open AccessThe Impact of TACI Mutations: From Hypogammaglobulinemia in Infancy to Autoimmunity in Adulthood
Common variable immunodeficiency (CVID) is considered the most common symptomatic antibody deficiency and, although mainly reported in adults, it may present from childhood. Few data on the impact of TACI defects on the clinical and immunological status of children are available. We screened 42 hypogammaglobulinemia children to investigate the frequency and mutational features of TACI defects. The genetic, clinical and immunological characterization was extended to 31 relatives of 11 children with TACI mutations. Of interest, our analysis showed a considerably higher mutation frequency in hypogammaglobulinemic children (13/42; 31%) than in other cohorts of adult patients. In seven out of nine families with the C104R variant, the prevalence of autoimmunity was significantly higher in C104R heterozygous relatives (8/15; 53%) than in those with no C104R mutation (1/11; 9%). Our data suggest a different impact of TACI mutations, from hypogammaglobulinemia in children to autoimmune disease in adulthood.